A5066306817- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- RNA modifications and cancer
- Cancer Cells and Metastasis
- Cancer therapeutics and mechanisms
- Epigenetics and DNA Methylation
- Medical Imaging and Pathology Studies
- Effects of Radiation Exposure
- Radiomics and Machine Learning in Medical Imaging
- Peptidase Inhibition and Analysis
- Cancer Immunotherapy and Biomarkers
- Retinoids in leukemia and cellular processes
- Medical Imaging Techniques and Applications
- Advanced Radiotherapy Techniques
- Colorectal Cancer Treatments and Studies
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Palliative Care and End-of-Life Issues
- Pleural and Pulmonary Diseases
- Cancer Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Occupational and environmental lung diseases
University of Michigan
2016-2025
Michigan Medicine
2007-2025
Michigan Center for Translational Pathology
2007-2023
U-M Rogel Cancer Center
2000-2021
Cornell University
2009-2018
American Society of Clinical Oncology
2015-2018
New York University
2018
Suburban Hospital
2018
Henry Ford Hospital
2018
Indiana University – Purdue University Indianapolis
2017
Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) placebo EP for previously untreated extensive-stage (ES) SCLC.Eligible were randomly assigned 1:1 to 200 mg once every 3 weeks or saline up 35 cycles 4 of EP. Primary end points progression-free survival (PFS; RECIST version 1.1, blinded central review) overall (OS) the...
Purpose In response to advances in the field, College of American Pathologists (CAP), International Association for Study Lung Cancer (IASLC), and Molecular Pathology (AMP) recently updated their recommendations molecular testing selection patients with lung cancer treatment targeted tyrosine kinase inhibitors. ASCO has a policy set procedures endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The guideline was reviewed developmental...
Neuroendocrine tumors account for approximately 20% of lung cancers; most (≈15%) are small cell cancer (SCLC). These NCCN Clinical Practice Guidelines in Oncology SCLC focus on extensive-stage because it occurs more frequently than limited-stage disease. is highly sensitive to initial therapy; however, patients eventually die recurrent In with disease, chemotherapy alone can palliate symptoms and prolong survival patients; long-term rare. Most cases attributable cigarette smoking; therefore,...
The NCCN Guidelines for Neuroendocrine and Adrenal Tumors provide recommendations the management of adult patients with neuroendocrine tumors (NETs), adrenal gland tumors, pheochromocytomas, paragangliomas. Management NETs relies heavily on site primary NET. These Insights summarize options 2018 updates to guidelines locoregional advanced disease, and/or distant metastasis originating from gastrointestinal tract, bronchopulmonary, thymus NETs.
The hepatocyte growth factor receptor gene (MET) exon 14 skipping (METex14) has recently been described a potential driver alteration in lung cancer targetable by mesenchymal-to-epithelial transition tyrosine kinase inhibitors (TKIs).Well-validated hybrid capture-based comprehensive genomic profiling was performed at the request of individual treating physicians.Of 11,205 cancers profiled profiling, 298 (2.7%) carcinomas harbored alterations predicted to cause METex14, including...
Purpose Radiation therapy is a critical component in the care of patients with non-small-cell lung cancer (NSCLC), yet cardiac injury after treatment significant concern. Therefore, we wished to elucidate incidence events and their relationship radiation dose heart. Patients Materials Study eligibility criteria included stage II III NSCLC treated on one four prospective trials at two centers from 2004 2013. All were reviewed graded per Common Terminology Criteria for Adverse Events (v4.03)....
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These Insights focus on recent updates to the SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For 2018 update, new sections were added “Signs Symptoms SCLC” “Principles Pathologic Review.”
Abstract Background Few intervention programs assist patients and their family caregivers to manage advanced cancer maintain quality of life (QOL). This study examined (i) whether patient–caregiver dyads (i.e., pairs) randomly assigned a brief or extensive dyadic (the FOCUS Program) had better outcomes than usual care (ii) patients' risk for distress other factors moderated the effect program on outcomes. Methods Advanced ( N = 484 dyads) were stratified by baseline (high versus low), type...
Our previous studies demonstrated that tumors significantly decrease in size and metabolic activity after delivery of 45 Gy fractionated radiatiotherapy (RT), shrinkage is greater than anatomic shrinkage. This study aimed to determine whether 18F-fludeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) acquired during the course treatment provides an opportunity deliver higher-dose radiation more aggressive areas tumor improve local control without increasing RT-induced...
9017 Background: Immune checkpoint inhibitor (ICPI) therapies, including nivolumab and pembrolizumab, have been FDA-approved in squamous non-squamous non-small cell (LC). Current IHC based diagnostics are challenged by assay slide scoring issues, more robust comprehensive biomarkers of ICPI efficacy needed. Methods: Comprehensive genomic profiling (CGP) was performed on FFPE specimens during the course clinical care. TMB (mutations/Mb) assessed as number somatic, coding, base substitution...
Abstract Oncogenic RET fusions occur in diverse cancers. Pralsetinib is a potent, selective inhibitor of receptor tyrosine kinase. ARROW ( NCT03037385 , ongoing) was designed to evaluate pralsetinib efficacy and safety patients with advanced -altered solid tumors. Twenty-nine 12 different fusion–positive tumor types, excluding non-small-cell lung cancer thyroid cancer, who had previously received or were not candidates for standard therapies, enrolled. The most common fusion partners 23...
RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective inhibitor, previously demonstrated clinical activity patients with fusion-positive NSCLC the phase I/II ARROW study, including among treatment-naive patients. We report an updated analysis from study.ARROW is multi-cohort, open-label, study. Eligible were ≥18 years age locally advanced or metastatic solid tumours and Eastern Cooperative...
Context.— Rapid advancements in the understanding and manipulation of tumor-immune interactions have led to approval immune therapies for patients with non–small cell lung cancer. Certain checkpoint inhibitor require use companion diagnostics, but methodologic variability has uncertainty around test selection implementation practice. Objective.— To develop evidence-based guideline recommendations testing immunotherapy/immunomodulatory biomarkers, including programmed death ligand-1 (PD-L1)...
The vascular endothelial growth factor (VEGF) family is a novel regulator of cell proliferation. We assessed the mRNA expression VEGF, VEGF type C (VEGF-C) and their receptors together with microvessel density (VD) microlymphatic vessel (LVD) in pursuit connection prognostic value malignant pleural mesothelioma (MPM). used four human MPM lines, 54 tumours five normal tissues. Expression levels for ligands were by semiquantitative reverse transcriptase polymerase chain reaction analysis....
PURPOSE A large community-based cancer registry was analyzed to determine if the clinicopathologic characteristics and/or survival rates of lung patients under 50 years age at diagnosis differ from those or greater diagnosis. PATIENTS AND METHODS Data regarding demographics, stage, histology, initial therapy, and were obtained on all with primary bronchogenic carcinoma registered in metropolitan Detroit Surveillance, Epidemiology End Results (SEER) 1973 1992. RESULTS Of 31,266 patients, 9.0%...
The cancer stem cell theory postulates that tumors contain a subset of cells with properties self-renewal, differentiation, and tumor initiation. purpose this study is to determine the role Notch activity in identifying lung cells.We investigated adenocarcinoma using GFP reporter construct γ-secretase inhibitor (GSI), which inhibits pathway activity.Transduction identified high (GFP-bright). GFP-bright had ability form more spheres serum-free media were able generate both GFP-dim (lower...